Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 1,623,177,000, a decrease of 53.5% compared to RMB 3,488,094,000 in 2024[3]. - Gross profit for the same period was RMB 775,080,000, down 10.0% from RMB 861,672,000 in 2024[3]. - Operating loss increased to RMB (853,301,000), a rise of 126.9% from RMB (376,141,000) in the previous year[3]. - The adjusted net loss (non-IFRS measure) was RMB (182,129,000), up 56.9% from RMB (116,093,000) in 2024[3]. - The company reported a net loss of RMB 968.5 million for the reporting period, an increase of 97.1% year-on-year, primarily due to losses from divested subsidiaries and one-time provisions[17]. - The company recorded a net loss of approximately RMB 491.4 million for the fiscal year ending December 31, 2024, increasing by 97.1% to approximately RMB 968.5 million for the fiscal year ending December 31, 2025, primarily due to losses from the sale of subsidiaries[51]. - The company reported a basic loss per share of RMB 1.52 for the year ended December 31, 2025, compared to RMB 0.89 for 2024, based on a weighted average of 609,853,000 shares outstanding[114]. Revenue Breakdown - Revenue from in-hospital solutions was RMB 1,188.8 million, a decrease of 55.7% from RMB 2,683.3 million in the previous year[23]. - Revenue from outpatient solutions dropped by 46.0% from approximately RMB 804.8 million in 2024 to approximately RMB 434.4 million in 2025, primarily due to a strategic focus on AI-assisted pharmacy solutions and P2M solutions[39]. - Revenue from the P2M solution reached RMB 419.1 million, a significant increase of 46.6% compared to RMB 286.0 million in the previous year[21]. - The P2M solutions generated total revenue of RMB 504.5 million as of December 31, 2025, representing a substantial increase of 57.5% compared to December 31, 2024, achieving profitability[14]. - Revenue from subscription solutions (precision marketing) was RMB 253.9 million, a decrease of 9.9% from RMB 281.9 million in the previous year[23]. Operational Metrics - The average daily online effective prescription volume exceeded one million during the reporting period[7]. - The number of registered users on the company's pharmacy platform reached approximately 61.4 million, with online prescriptions totaling 371.6 million, reflecting a year-on-year growth of 40.5%[27]. - The company has connected over 18,000 hospitals, capturing 40% of the top 100 hospitals in China, with a penetration rate of over 30% in tertiary public hospitals[6]. - The company has installed its AI-driven pharmacy platform in 275,613 pharmacies, representing approximately 40% of the total pharmacies in China[7]. - The number of pharmacies using the AI-driven pharmacy platform increased by 13.6% to 275,613 in 2025[31]. Cost and Expenses - The total cost of goods sold was RMB 754,616,000 in 2025, significantly lower than RMB 2,565,680,000 in 2024, representing a decrease of approximately 70.7%[109]. - Sales cost decreased by 67.7% to approximately RMB 848.1 million in 2025, outpacing the revenue decline due to a shift towards higher-margin solutions[40]. - Personnel-related costs for the year ending December 31, 2025, amounted to approximately RMB 786.5 million, a decrease from RMB 842.6 million for the year ending December 31, 2024[69]. - The company's employee compensation expenses decreased to RMB 290,697,000 in 2025 from RMB 355,251,000 in 2024, a decline of approximately 18.1%[107]. Cash Flow and Liquidity - The company achieved a net cash inflow from operating activities of RMB 66.8 million in 2025, compared to a net cash outflow of RMB 148.4 million in the same period of 2024, indicating a necessary transformation[13]. - Cash and cash equivalents as of December 31, 2025, were approximately RMB 267.6 million, down from RMB 304.8 million as of December 31, 2024[56]. - The company's debt-to-asset ratio increased to 51.1% as of December 31, 2025, from 42.1% as of December 31, 2024, primarily due to a faster decline in total assets compared to total liabilities[63]. Strategic Focus and Future Plans - The company is focusing on a P2M strategy to achieve stable cash flow and profitability in the short term, with a long-term goal of monetizing data assets[13]. - The company plans to continue investing in product and technology innovation, focusing on medical AI models to strengthen its market position[36]. - The company aims to enhance the healthcare ecosystem's efficiency through technology and continues to build digital infrastructure for chronic disease management[9]. - The company has received sales approval for an important P2M pipeline product, which is expected to enhance long-term market expansion and profitability[15]. Corporate Governance and Compliance - The audit committee has reviewed the accounting policies and consolidated financial information for the year ending December 31, 2025[75]. - There were no significant lawsuits or arbitrations involving the company during the reporting period[78]. - The company did not engage in any significant investments or acquisitions during the year ended December 31, 2025[59][60]. Employee and Workforce - The company employed a total of 887 employees as of December 31, 2025, with the majority located in Hangzhou, Shanghai, and other offices in China[67]. - As of December 31, 2025, the total number of employees is 887, with 703 in sales and marketing, 66 in R&D, 47 in general and administration, and 71 in other functions[68].

（於開曼群島註冊成立的有限公司） （股份代號：9955） 董事會召開日期 智雲健康科技集團*（「本公司」）董事（「董事」）會（「董事會」）兹通告謹定於2026 年3月26日（星期四）舉行董事會會議，以考慮及批准本公司及其附屬公司截至 2025年12月31日止年度之年度業績及其發佈，以及處理其他事項。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 智雲健康科技集團* 董事長、執行董事兼 首席執行官 匡明 香港，2026年3月16日 於本公告日期，董事會由執行董事匡明先生及胡悅女士，以及獨立非執行董事洪偉力博士、 張賽音先生及Ang Khai Meng先生組成。 * 僅供識別 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 1 ...

Group 1 - As of February 26, a total of 124 stocks reached a 52-week high, with Changying Group (控股) (00689), Qiaoyang International Holdings (08070), and MS CONCEPT (08447) leading the high rate at 41.39%, 41.05%, and 39.66% respectively [1] - The closing prices and highest prices for the top three stocks are as follows: Changying Group (0.335, 0.345), Qiaoyang International Holdings (1.150, 1.340), and MS CONCEPT (0.072, 0.081) [1] - Other notable stocks that reached new highs include Wanwei International (00167) at 29.79%, Hongcheng Environmental Technology (02265) at 25.93%, and Putian Communication Group (01720) at 24.32% [1] Group 2 - The report also lists stocks that reached new lows, with Xinda Holdings (08471) showing a decline of 21.67%, XI Ernan Samsung - U (09347) down by 16.67%, and XI Ernan Samsung (07347) decreasing by 15.24% [4] - The lowest prices for the stocks mentioned include: Xinda Holdings (0.048, 0.047), XI Ernan Samsung - U (0.036, 0.035), and XI Ernan Samsung (0.281, 0.278) [4] - Other stocks with significant declines include Xishi Electric Vehicle New Materials (06128) at -14.29% and Zhiyun Health (09955) at -10.13% [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 基於目前可得的資料，董事會認為預期虧損增加主要是由於本集團進行戰略 轉型重組業務模式，圍繞核心人工智能能力，重點打造高質量及可產生現金流 的增長。此導致就出售若干子公司確認大額減值虧損及錄得與交易對手方正 處於重大訴訟或接受司法調查的業務相關的一次性特定撥備。由於從利潤率 較低的醫療用品銷售業務戰略性剝離及轉型至聚焦於經營效率較高的人工智 能驅動型P2M業務，本集團於報告年度的經營活動現金流入淨額預期將介乎約 人民幣50百萬元至約人民幣80百萬元，而截至2024年12月31日止年度的經營活 動現金流出淨額則約為人民幣148.4百萬元。 本公告所載的資料僅基於本公司參考本公司目前可得的資料及本集團於報告 年度的未經審核綜合管理賬目後所作出的初步評估，並非基於經本公司獨立 核數師或董事會審核委員會審核或審閱的財務數據或其他資料。因此，上述數 據可能會有所調整。本集團於報告年度的實際財務業績可能與本公告所披露 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 1 ...

Group 1 - The core point of the article is that Hu Yue, an executive director of Zhiyun Health (09955.HK), increased his shareholding by purchasing 117,700 shares at an average price of HKD 1.05 per share, totaling approximately HKD 123,600 [1][2] - After the purchase, Hu Yue's total shareholding reached 117,700 shares, representing 0.02% of the company's issued shares [1][2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | ...

Core Viewpoint - Zhiyun Health (09955) announced the appointment of Ms. Hu Yue as an executive director and a member of the board nomination committee, effective from December 27, 2025 [1] - Ms. Zuo Yinghui has resigned from her position as an executive director and will no longer be a member of the nomination committee, also effective from December 27, 2025, due to her desire to dedicate more time to other professional matters [1] Summary by Category - **Management Changes** - Ms. Hu Yue appointed as executive director and board nomination committee member effective December 27, 2025 [1] - Ms. Zuo Yinghui resigned from executive director position and nomination committee member effective December 27, 2025 [1] - **Reason for Resignation** - Ms. Zuo Yinghui's resignation is attributed to her intention to focus more on other professional commitments [1]

Group 1 - Zhiyun Health (09955) announced the appointment of Ms. Hu Yue as an executive director and a member of the board nomination committee, effective from December 27, 2025 [1] - Ms. Zuo Yinghui has resigned from her position as an executive director and will no longer be a member of the nomination committee, effective from December 27, 2025, due to her desire to devote more time to other professional matters [1]